Skip to content
DataLookout
Menu

NCT05976139

Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 1 year 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jul 30, 2025 to Dec 30, 2026 Show 6 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 1 of 3 entries
    • Study description revised
    • Site details revised
    • Publications: details revised at 15 of 15 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 25, 2023 to Sep 6, 2023
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

assessment of significative change in retinal oedema compared to baseline
Timeframe: up to 24 months

Secondary (3)

To study changes in visual acuity between before and after treatment
To study the retinal function in the macular area before and after treatment.
To study the retinal perfusion of the macular area by OCT-angiography before and after treatment.

Arms and interventions

inherited retinal dystrophies with macular oedemaExperimental

Laser treatment will be performed in patients with macular edema in IRD (experimental arm) who: * underwent treatment with diuretics or nutritional drainage products for 3 months and subsequent 'wash-out' of one month 17,18 and had no reduction in macular oedema, in terms of central retinal thickness, of at least 20% compared with the initial assessment * they have had an intravitreal injection of anti-VEGF or steroids, and after 3 months there is no reduction in central retinal thickness (CRT) of at least 20% compared to the initial assessment * have after 3 months a thickness reduction \<10% compared to baseline assessment, following initial treatment with micropulsed laser, and may be candidates for repeating treatment; * are not eligible for diuretic therapy due to the presence of comorbidities.

Devices: subthreshold treatment with micropulsed laser

Sites

1 site in 1 country

  • IRCSS Fondazione G:B:BiettiRome, RM, Italy